# Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

Source: https://onco.cc/trials/nct05583552/  
OnCo record `nct05583552` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Imetelstat in myelodysplastic syndromes / neoplasms and acute myeloid leukaemia, run by GCP-Service International West GmbH, active and no longer recruiting.

## Summary

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy is a phase 2 interventional study registered as NCT05583552 by GCP-Service International West GmbH, with 46 participants enrolled, started 2023-06-05 and due to reach its primary completion in 2025-03-27. Interventions recorded: Imetelstat sodium. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05583552
- Phase: 2
- Setting: A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients With HR Myelodysplastic Syndromes or AML Failing HMA-based Therapy
- Sponsor: GCP-Service International West GmbH
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT05583552: https://clinicaltrials.gov/study/NCT05583552

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [Imetelstat](https://onco.cc/drugs/imetelstat/)
- companies: [Geron Corporation](https://onco.cc/companies/geron/)

---
JSON: https://onco.cc/api/v1/entities/nct05583552.json